Jim Cirigliano
Articles by Jim Cirigliano
| 3 min read
Companies will focus on gene-silencing targets in the areas of cardio-metabolic disease, neurodegeneration and pain
| 3 min read
BLU-782 offers hope for patients with difficult-to-target genetic disease that turns muscle to bone
| 3 min read
New studies indicate a valid, predictive biomarker for mCRPC
| 3 min read
International CRO gobbles up drug transporter and drug-drug interaction specialist company
| 3 min read
Opiant announces development of intranasal nalmefene for treatment of opioid overdose
| 3 min read
Deleted gene that immortalizes MSCs may be critical to their function
| 3 min read
Protein expression may predict risk of colorectal cancer recurrence
| 4 min read
Collaboration to explore RNA interference therapeutics for liver disease
| 3 min read
Phase 3 study on Taltz finds sustained improvements in joint pain and skin clearance in extension period
| 3 min read
Multi-organ-on-a-chip model promises wide-ranging applications
